Mechanisms of Adsorption and Surface-Mediated Aggregation of Intrinsically Disordered Protein Tau at Model Surfaces

The adsorption and aggregation of an intrinsically disordered soluble protein, tau, into insoluble filaments is a defining hallmark of many neurodegenerative diseases, commonly referred to as tauopathies. In its native state, the protein tau’s function is to promote the assembly, and aid in the stabilization of microtubules. The microtubules allow for material transport through the axon, to and from the neuron. While the presence of aggregated tau protein fibrils are hypothesized to accelerate neuronal degradation, possibly by destabilizing microtubules, or disrupting cell membranes, more recent research has established the presence of soluble oligomeric species as being cytotoxic. These results necessitate a complete fundamental understanding of the governing principles that modulate the initial steps in the mechanisms of tau protein aggregation. The macromolecular environment, including the presence of surfaces such as the cell membrane, and the presence of macromolecules in a crowded environment, has been implicated in the aggregation of tau protein. However, the exact role of surfaces in modulating Tau protein aggregation has not been explored in detail. We hypothesize that Tau protein aggregation at model surfaces is modulated by two factors, the physicochemical properties of the surfaces, as well as the biochemistry of the protein molecules. The work presented in this thesis project employs a combination of biophysical techniques to study the adsorption and aggregation of a wild type and several mutations of tau protein at model surfaces. A Quartz Crystal Microbalance with Dissipation (QCM-D) was used to monitor the adsorption of different tau species at nanomolar concentrations, mimicking the in vivo situation, to surfaces with different surface charge, wettability and softness, while Atomic Force Microscopy (AFM) was utilized to obtain direct visualization of the proteins at these different surfaces. Our results indicate that the hydrophobic amino acid sequence in the microtubule binding region was the leading force driving the adsorption of tau proteins to different surfaces. Further, AFM images provided direct evidence of the presence of oligomeric tau species at the interfaces, establishing that the solid surface did in fact provide a template for the tau protein to form aggregates. Adsorption of different tau protein mutations to phospholipid covered surfaces of different fluidity indicated that tau protein oligomers can also cause destabilization or disintegration of lipid bilayers. Such disintegration may well be the cause of observed cell death in several tauopathies. In summary, this thesis establishes that both protein biochemistry and the physicochemical properties of the surface modulate surface mediated aggregation. The work described in this thesis also provides a foundation for further research focused on the role of surfaces as templates that mediate tau aggregation pathway in vivo. A complete understanding of the mechanisms of tau aggregation will ultimately lead to strategies for therapeutic solutions for neurodegenerative diseases

Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL-GAP4): A multicentre, randomized, controlled phase III study protocol

Introduction: Preliminary evidence supports the beneficial role of physical activity on prostate cancer outcomes. This phase III randomised controlled trial (RCT) is designed to determine if supervised high-intensity aerobic and resistance exercise increases overall survival (OS) in patients with metastatic castrate-resistant prostate cancer (mCRPC). Methods and analysis: Participants (n=866) must have histologically documented metastatic prostate cancer with evidence of progressive disease on androgen deprivation therapy (defined as mCRPC). Patients can be treatmentnaive for mCRPC or on first-line androgen receptor-targeted therapy for mCRPC (ie, abiraterone or enzalutamide) without evidence of progression at enrolment, and with no prior chemotherapy for mCRPC. Patients will receive psychosocial support and will be randomly assigned (1:1) to either supervised exercise (high-intensity aerobic and resistance training) or self-directed exercise (provision of guidelines), stratified by treatment status and site. Exercise prescriptions will be tailored to each participant’s fitness and morbidities. The primary endpoint is OS. Secondary endpoints include time to disease progression, occurrence of a skeletal-related event or progression of pain, and degree of pain, opiate use, physical and emotional quality of life, and changes in metabolic biomarkers. An assessment of whether immune function, inflammation, dysregulation of insulin and energy metabolism, and androgen biomarkers are associated with OS will be performed, and whether they mediate the primary association between exercise and OS will also be investigated. This study will also establish a biobank for future biomarker discovery or validation. Ethics and dissemination: Validation of exercise as medicine and its mechanisms of action will create evidence to change clinical practice. Accordingly, outcomes of this RCT will be published in international, peer-reviewed journals, and presented at national and international conferences. Ethics approval was first obtained at Edith Cowan University (ID: 13236 NEWTON), with a further 10 investigator sites since receiving ethics approval, prior to activation. Trial registration number: NCT02730338

Phospholipid Composition Modulates Carbon Nanodiamond-Induced Alterations in Phospholipid Domain Formation

This document is the Accepted Manuscript version of a Published Work that appeared in final form in Langmuir, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://doi.org/10.1021/la504923j.The focus of this work is to elucidate how phospholipid composition can modulate lipid nanoparticle interactions in phospholipid monolayer systems. We report on alterations in lipid domain formation induced by anionically engineered carbon nanodiamonds (ECNs) as a function of lipid headgroup charge and alkyl chain saturation. Using surface pressure vs area isotherms, monolayer compressibility, and fluorescence microscopy, we found that anionic ECNs induced domain shape alterations in zwitterionic phosphatidylcholine lipids, irrespective of the lipid alkyl chain saturation, even when the surface pressure vs area isotherms did not show any significant changes. Bean-shaped structures characteristic of dipalmitoylphosphatidylcholine (DPPC) were converted to multilobed, fractal, or spiral domains as a result of exposure to ECNs, indicating that ECNs lower the line tension between domains in the case of zwitterionic lipids. For membrane systems containing anionic phospholipids, ECN-induced changes in domain packing were related to the electrostatic interactions between the anionic ECNs and the anionic lipid headgroups, even when zwitterionic lipids are present in excess. By comparing the measured size distributions with our recently developed theory derived by minimizing the free energy associated with the domain energy and mixing entropy, we found that the change in line tension induced by anionic ECNs is dominated by the charge in the condensed lipid domains. Atomic force microscopy images of the transferred anionic films confirm that the location of the anionic ECNs in the lipid monolayers is also modulated by the charge on the condensed lipid domains. Because biological membranes such as lung surfactants contain both saturated and unsaturated phospholipids with different lipid headgroup charges, our results suggest that when studying potential adverse effects of nanoparticles on biological systems the role of lipid compositions cannot be neglected

Phospholipid Composition Modulates Carbon Nanodiamond-Induced Alterations in Phospholipid Domain Formation

The focus of this work is to elucidate how phospholipid composition can modulate lipid nanoparticle interactions in phospholipid monolayer systems. We report on alterations in lipid domain formation induced by anionically engineered carbon nanodiamonds (ECNs) as a function of lipid headgroup charge and alkyl chain saturation. Using surface pressure vs area isotherms, monolayer compressibility, and fluorescence microscopy, we found that anionic ECNs induced domain shape alterations in zwitterionic phosphatidylcholine lipids, irrespective of the lipid alkyl chain saturation, even when the surface pressure vs area isotherms did not show any significant changes. Bean-shaped structures characteristic of dipalmitoylphosphatidylcholine (DPPC) were converted to multilobed, fractal, or spiral domains as a result of exposure to ECNs, indicating that ECNs lower the line tension between domains in the case of zwitterionic lipids. For membrane systems containing anionic phospholipids, ECN-induced changes in domain packing were related to the electrostatic interactions between the anionic ECNs and the anionic lipid headgroups, even when zwitterionic lipids are present in excess. By comparing the measured size distributions with our recently developed theory derived by minimizing the free energy associated with the domain energy and mixing entropy, we found that the change in line tension induced by anionic ECNs is dominated by the charge in the condensed lipid domains. Atomic force microscopy images of the transferred anionic films confirm that the location of the anionic ECNs in the lipid monolayers is also modulated by the charge on the condensed lipid domains. Because biological membranes such as lung surfactants contain both saturated and unsaturated phospholipids with different lipid headgroup charges, our results suggest that when studying potential adverse effects of nanoparticles on biological systems the role of lipid compositions cannot be neglected

Air-sea CO2 exchange and carbon source/sink dynamics in the Southeast Beaufort Sea

International audienc

Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.

IntroductionPreliminary evidence supports the beneficial role of physical activity on prostate cancer outcomes. This phase III randomised controlled trial (RCT) is designed to determine if supervised high-intensity aerobic and resistance exercise increases overall survival (OS) in patients with metastatic castrate-resistant prostate cancer (mCRPC).Methods and analysisParticipants (n=866) must have histologically documented metastatic prostate cancer with evidence of progressive disease on androgen deprivation therapy (defined as mCRPC). Patients can be treatment-naïve for mCRPC or on first-line androgen receptor-targeted therapy for mCRPC (ie, abiraterone or enzalutamide) without evidence of progression at enrolment, and with no prior chemotherapy for mCRPC. Patients will receive psychosocial support and will be randomly assigned (1:1) to either supervised exercise (high-intensity aerobic and resistance training) or self-directed exercise (provision of guidelines), stratified by treatment status and site. Exercise prescriptions will be tailored to each participant's fitness and morbidities. The primary endpoint is OS. Secondary endpoints include time to disease progression, occurrence of a skeletal-related event or progression of pain, and degree of pain, opiate use, physical and emotional quality of life, and changes in metabolic biomarkers. An assessment of whether immune function, inflammation, dysregulation of insulin and energy metabolism, and androgen biomarkers are associated with OS will be performed, and whether they mediate the primary association between exercise and OS will also be investigated. This study will also establish a biobank for future biomarker discovery or validation.Ethics and disseminationValidation of exercise as medicine and its mechanisms of action will create evidence to change clinical practice. Accordingly, outcomes of this RCT will be published in international, peer-reviewed journals, and presented at national and international conferences. Ethics approval was first obtained at Edith Cowan University (ID: 13236 NEWTON), with a further 10 investigator sites since receiving ethics approval, prior to activation.Trial registration numberNCT02730338

Surface Ocean CO2 Atlas (SOCAT) V6

The Surface Ocean CO2 Atlas (SOCAT) is a synthesis activity by the international marine carbon research community (>100 contributors). SOCAT version 6 has 23.4 million quality-controlled, surface ocean fCO2 (fugacity of carbon dioxide) observations from 1957 to 2017 for the global oceans and coastal seas. Calibrated sensor data are also available. Automation allows annual, public releases. SOCAT data is discoverable, accessible and citable. SOCAT enables quantification of the ocean carbon sink and ocean acidification and evaluation of ocean biogeochemical models. SOCAT represents a milestone in biogeochemical and climate research and in informing policy